Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG

Journal of Nuclear Medicine

Volumn 44, Issue 9, 2003, Pages 1426-1431

  Buck, Andreas K ^a   Halter, Gisela ^a   Schirrmeister, Holger ^a   Kotzerke, Jörg ^a   Wurziger, Imke ^a   Glatting, Gerhard ^a   Mattfeldt, Torsten ^a   Neumaier, Bernd ^a   Reske, Sven N ^a   Hetzel, Martin ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

18F FDG; 18F FLT; Ki 67; Lung cancer; Proliferation

Indexed keywords

3' FLUOROTHYMIDINE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; MONOCLONAL ANTIBODY KI 67; THYMIDINE DERIVATIVE; TRACER; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BIOPSY; CALCULATION; CANCER SURGERY; CARCINOMA IN SITU; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMAGING; INTERMETHOD COMPARISON; LINEAR REGRESSION ANALYSIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG TUMOR; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANK SUM TEST; STAINING; STANDARDIZATION; STATISTICAL ANALYSIS; THORAX RADIOGRAPHY; TUMOR DIAGNOSIS; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; LUNG COIN LESION; METABOLISM; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STATISTICS;

ADULT; AGED; COIN LESION, PULMONARY; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0142181279     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer J Nucl Med. 2001;42:1596-1604.
2. Kalff VV, Hicks RJ, MacManus M, et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer, a prospective study J Clin Oncol 2001;19:111-118.
3. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285:914-924
4. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging, physiologic and benign variants Radiographics. 1999;19:61-77
5. Buck AC, Schirrmeister HH, Guhlmann CA, et al. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med. 2001;42:721-725.
6. Dosaka-Akita H, Hommura F, Mishina T, et al. A risk-stratification model of non-small cell lung cancers using cyclin E. Ki-67. and ras p21: different roles of G1 cyclins in cell proliferation and prognosis Cancer Res. 2001;61:2500-2504.
7. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography Clin Cancer Res. 2000;6:3837-3844
8. Higashi K, Ueda Y, Yagishita M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 2000;41:85-92.
9. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201-3206
10. Mac Manus MP, Hicks RJ, Ball DL, et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001;92:886-895
11. Shields AF, Grierson JR, Kozawa SM, Zheng M. Development of labeled thymidine analogs for imaging tumor proliferation Nucl Med Biol 1996;23: 17-22.
12. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
13. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL, Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-1217.
14. Buck AK, Schirrmeister H, Hetzel M, et al. 3-deoxy-3-[(18)F] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002;62:3331-3334.
15. 18F]FLT) J Radioanal Nucl Chem. 2000;24:843-846.
16. Schmidlin P. Iterative algorithms for emission tomography [in German]. Nuklearmedizin. 1990;3:155-158.
17. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology. 1999;212:803-809.
18. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol. 1998;16:2142-2149.
19. Kubota R, Kubota K, Yamada S, Tada M, Takahashi T, Iwata R Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18- fluorodeoxyglucose uptake. J Nucl Med. 1994;35:104-112.
20. Marom EM, Aloia TA, Moore MB, et al. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer. 2001,33:99-107.
21. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med. 1999;40:556-565
22. 3H]thymidine, and gallium-67. J Nucl Med. 1991;32:2118-2123.
23. Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of (18)fluoro-deoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-387.
24. 38F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42:9-16.
25. Eary JF, Mankoff DA, Spence AM, et al 2-[C-11]thymidme imaging of malignant brain tumors. Cancer Res. 1999;59:615-621
26. 11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl Med Biol. 1995;22:783-789.
27. 124I]iododeoxyuridine. Cancer Res. 2000;60:624-635.
28. 18F]FLT: portrait of a proliferation marker. Eur J Nucl Med Mol Imaging. 2002;29:165-169.
29. 18F-FDG PET. J Nucl Med. 2002;43:1304-1309
30. Spaepen K, Stroobants S, Dupont P, et al Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13:1356-1363.
31. Flamen P, Van Cutsem E, Lerut A, et al Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002;13:361-368
32. Spence AM, Muzi M, Graham MM, et al. 2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome Clin Cancer Res. 2002;8:971-979
33. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-3065
34. Dittmann H, Dohmen BM, Kehlbach R, et al. Early changes in [(18)F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging. 2002;29:1462-1469.